Prognostic relevance of KRAS and BRAF mutations in Japanese patients with colorectal cancer

Myelodysplastic Syndromes

(2017) Peter L. Greenberg et al.   Journal of the National Comprehensive Cancer Network

KRAS mutations detected by the amplification refractory mutation system–Scorpion assays strongly correlate with therapeutic effect of cetuximab

(2011) H Bando et al.   BRITISH JOURNAL OF CANCER

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

(2011) T Yokota et al.   BRITISH JOURNAL OF CANCER

Molecular Analysis of Colorectal Tumors within a Diverse Patient Cohort at a Single Institution

(2011) B. E. Sylvester et al.   CLINICAL CANCER RESEARCH

Differential gene expression signatures between colorectal cancers with and without KRAS mutations: Crosstalk between the KRAS pathway and other signalling pathways

(2011) Toshiaki Watanabe et al.   EUROPEAN JOURNAL OF CANCER

Lymph node ratio is a powerful prognostic index in patients with stage III distal rectal cancer: a Japanese multicenter study

(2011) Hirotoshi Kobayashi et al.   INTERNATIONAL JOURNAL OF COLORECTAL DISEASE

Conversion Chemotherapy Using Cetuximab plus FOLFIRI Followed by Bevacizumab plus mFOLFOX6 in Patients with Unresectable Liver Metastases from Colorectal Cancer

(2011) K. Uehara et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Cetuximab Plus Capecitabine and Irinotecan Compared With Cetuximab Plus Capecitabine and Oxaliplatin As First-Line Treatment for Patients With Metastatic Colorectal Cancer: AIO KRK-0104—A Randomized Trial of the German AIO CRC Study Group

(2011) Nicolas Moosmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Colorectal Cancer Epigenetics: Complex Simplicity

(2011) Manon van Engeland et al.   JOURNAL OF CLINICAL ONCOLOGY

Value of Mismatch Repair, KRAS, and BRAF Mutations in Predicting Recurrence and Benefits From Chemotherapy in Colorectal Cancer

(2011) Gordon Hutchins et al.   JOURNAL OF CLINICAL ONCOLOGY

Microsatellite Instability and Loss of Heterozygosity at Chromosomal Location 18q: Prospective Evaluation of Biomarkers for Stages II and III Colon Cancer—A Study of CALGB 9581 and 89803

(2011) Monica M. Bertagnolli et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab Plus Irinotecan, Fluorouracil, and Leucovorin As First-Line Treatment for Metastatic Colorectal Cancer: Updated Analysis of Overall Survival According to Tumor KRAS and BRAF Mutation Status

(2011) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive and Prognostic Markers in Colorectal Cancer

(2011) Ben George et al.   Current Oncology Reports

Analyzing the Risk of Recurrence after Mastectomy for DCIS: A New Use for the USC/Van Nuys Prognostic Index

(2010) Leah Kelley et al.   ANNALS OF SURGICAL ONCOLOGY

KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis

(2010) V Deschoolmeester et al.   BRITISH JOURNAL OF CANCER

Molecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer

(2010) Alberto Bardelli et al.   JOURNAL OF CLINICAL ONCOLOGY

KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer

(2010) Wendy De Roock et al.   LANCET ONCOLOGY

Microsatellite instability in colorectal cancer—the stable evidence

(2010) Eduardo Vilar et al.   Nature Reviews Clinical Oncology

Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial

(2009) Arnaud D. Roth et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Basis of Colorectal Cancer

(2009) Sanford D. Markowitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Exclusive KRAS mutation in microsatellite-unstable human colorectal carcinomas with sequence alterations in the DNA mismatch repair gene, MLH1

(2008) Yan Zhao et al.   GENE

Using Predictive Biomarkers to Select Patients With Advanced Colorectal Cancer for Treatment With Epidermal Growth Factor Receptor Antibodies

(2008) Rachel Wong et al.   JOURNAL OF CLINICAL ONCOLOGY